EP-458 Robotic surgery improves outcomes for patients with benign and malignant colorectal conditions

Abstract

Abstract Aims Robotic surgery represents the newest minimally invasive technology available to reduce the impact of surgery and provides unique benefits in pelvic access of the technically challenging colorectal resections. The purpose of this study was to assess the feasibility and clinical outcomes of robotic resections at our trust. Methods A series of 106 consecutive patients who underwent robotic surgery between October 2020 and January 2021 was analyzed retrospectively in terms of demographics, perioperative and 30-day postoperative outcomes. Patients divided in three groups: colorectal cancer (CRC), IBD and diverticular disease. Results Seventy-four patients underwent robotic resection due to CRC. Fifty-two per cent (n=39/74) had sigmoid cancer followed by right sided colon cancer in 22%(n=16/74) and rectal cancer in 26%(n=19/74). Pathologically complete resection (R0) was achieved in all patients with a median lymph node ratio of 0.14. Twenty-two patients were included in the IBD group (77% Crohn's disease). Four patients underwent robotic resection due to fistulating diverticular disease. For all the groups there were no conversions to open surgery. Return of gut function was noted within 48 hours in 91% of the patients. All patients were discharged on their baseline Hb with no need for iron replacement therapy or blood transfusion. The median length of hospital stay was 5 days. There was no reported 30-day mortality. Conclusion Robotic surgery is feasible, safe and improves clinical and surgical outcomes. This novel approach ensures that surgery remains minimally invasive, leading to a significant reduction in length of hospital stay, and rapid postoperative recovery.